Prevalence of hepatitis C virus genotypes and subtypes in Lebanese population and major high risk groups

Rached, Antoine Abou; Yaghi, César; Khalil, Leda; Saba, Jowana; Ammar, Walid

doi:10.1016/j.ajg.2017.05.001

Cited by 7 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of HCV in Lebanon is low (0.2%) (7) with GT1 being the most prevalent genotype, followed by GT4 then GT3 (8). This study highlighted the demographics of the HCV epidemic in Lebanon.…”

Section: Discussionmentioning

confidence: 75%

Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection

et al. 2018

Self Cite

View full text Add to dashboard Cite

Objectives:The treatment of hepatitis C has dramatically improved since the introduction of new direct-acting antivirals (DAAs). The aim of this study was to assess the efficacy and safety of all oral DAAs, with or without ribavirin, in the treatment of naive and treatment experienced hepatitis C virus (HCV) Lebanese patients. Methods:This study reviewed all cases approved for hepatitis C treatment with DAAs, according to Lebanese guidelines for treatment of HCV at the Ministry of Public Health from October 2015 to December 2016. Available data on age, gender, genotype (GT) and subtype, fibrosis stage, previous treatment (if present), new DAAs treatment, and sustained virological response at week 12 (SVR12) were collected.Results: During a period of 15 months, a total of 186 patients were treated with DAAs. In total, 57% were male. The mean age of the patients was 54.3 years. Genotype 1 was the most prevalent (45%), followed by genotype four (34%) and genotype three (12%). More than 72% of patients had advanced fibrosis (F3 -F4) before starting DAAs and 42% of patients were treatment experienced. Regarding the different DAAs protocols used, SVR12 was achieved in 93% of cases, while 4% did not achieve SVR. Furthermore, 3% of cases were either lost to follow up or had major adverse events. Sustained virological response at week 12 was 93%, 96%, and 94% in GT1, GT3, and GT4, respectively. In cirrhotic patients, SVR12 was 90%. There was no difference in SVR12 between treatment naive and treatmentexperienced patients. Hepatocellular carcinoma developed in five patients during the period of the study.Conclusions: This is the first real world Lebanese data concerning hepatitis C treatment with DAAs. It showed a satisfactory response rate irrespective of previous treatments or the stage of fibrosis.

show abstract

Section: Discussionmentioning

confidence: 75%

Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intravenous drug use and blood transfusion are the most common routes of transmission, followed by hemodialysis [ 23 , 27 ]. Vertical and sexual transmissions are the least common routes of infection, representing 0.2% and 0.3% of HCV transmission cases, respectively ( Table 2 ) [ 28 ].…”

Section: Hcv In Lebanonmentioning

confidence: 99%

“…At the national level, the most common HVC genotype is 1, followed by genotype 4 [ 19 , 27 , 31 , 32 , 33 ]. Genotype 3 is the most prevalent among PWIU and prisoners [ 19 , 27 , 31 , 32 , 33 ].…”

Section: Hcv In Lebanonmentioning

confidence: 99%

Challenges Facing Viral Hepatitis C Elimination in Lebanon

2023

View full text Add to dashboard Cite

Hepatitis C is a hepatotropic virus that causes progressive liver inflammation, eventually leading to cirrhosis and hepatocellular carcinoma if left untreated. All infected patients can achieve a cure if treated early. Unfortunately, many patients remain asymptomatic and tend to present late with hepatic complications. Given the economic and health burdens of chronic hepatitis C infection, the World Health Organization (WHO) has proposed a strategy to eliminate hepatitis C by 2030. This article describes the epidemiology of hepatitis C in Lebanon and highlights the challenges hindering its elimination. An extensive search was conducted using PubMed, Medline, Cochrane, and the Lebanese Ministry of Public Health–Epidemiologic Surveillance Unit website. Obtained data were analyzed and discussed in light of the current WHO recommendations. It was found that Lebanon has a low prevalence of hepatitis C. Incidence is higher among males and Mount Lebanon residents. A wide variety of hepatitis C genotypes exists among various risk groups, with genotype 1 being the most predominant. In Lebanon, many barriers prevent successful hepatitis C elimination, including the absence of a comprehensive screening policy, stigma, neglect among high-risk groups, economic collapse, and a lack of proper care and surveillance among the refugees. Appropriate screening schemes and early linkage to care among the general and high-risk populations are essential for successful hepatitis C elimination in Lebanon.

show abstract

“…Lebanon is ranked among the countries with a low endemicity profile for both viruses having a prevalence of 1.74% for HBV and 0.21% for HCV (8); HCV genotype 3 is the most prevalent genotype in the Lebanese PWID population followed by genotype 1 (9). The prevalence of these infections among PWID in Lebanon has previously been estimated at 2.5-5% for HBV and more than 50% for HCV, based on small scale reports (10).…”

Section: Introductionmentioning

confidence: 99%

Prevalence of hepatitis B and anti-hepatitis C virus antibody among people who inject drugs in the Lebanese population

Rached¹,

Nakhoul²,

Richa³

et al. 2020

East Mediterr Health J

Self Cite

View full text Add to dashboard Cite

Background: People who inject drugs (PWIDs) are prone to a number of blood-borne viral infections. Hepatitis B virus (HBV) and hepatitis C virus (HCV) constitute an important public health concern in this high risk group. Aims: We aimed to determine the prevalence of HBV and HCV antibody among PWIDs in Lebanon. Methods: We conducted a prospective cross-sectional study between June 2015 and June 2016 on PWIDs recruited through Lebanese nongovernmental organizations in collaboration with the Lebanese Ministry of Public Health. The participants were tested for HBs antigen and HCV antibody using rapid test kits. The prevalence of each virus was then calculated. The correlation between both infections and other possible risk factors was also analysed. Results: A total of 250 people were included in our study, of whom 98% were males. Mean age was 31.9 (standard deviation 8.7) years. The prevalence of HBsAg and anti-HCV among PWIDs was 1.2% and 15.6%, respectively. Older age, longer duration of drug use and lack of awareness were significantly correlated with a higher rate of HCV infection (P < 0.01). The high rate of needle sharing among our PWIDs significantly affected the prevalence of anti-HCVAb. Conclusion: PWIDs remain the subpopulation most affected with chronic HCV in Lebanon.

show abstract

Prevalence of hepatitis C virus genotypes and subtypes in Lebanese population and major high risk groups

Cited by 7 publications

References 21 publications

Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection

Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection

Challenges Facing Viral Hepatitis C Elimination in Lebanon

Prevalence of hepatitis B and anti-hepatitis C virus antibody among people who inject drugs in the Lebanese population

Contact Info

Product

Resources

About